Douglas Wolf
Appearances
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
- DateMay 9, 2023BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Speakers
Icahn School of Medicine, Mount SinaiSwedish Medical CenterWestern UniversityKatholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Cedars-Sinai Medical Center - DateMay 20, 2024Background: Women with inflammatory bowel disease (IBD) face the complexities of disease management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals with IBD persists due to concern for perianal disease and perineal trauma…
Presenter
University of California, San FranciscoSpeakers
University of North CarolinaThe University of ChicagoUniversity of California san francisco
